455 related articles for article (PubMed ID: 19307789)
21. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma.
Lo CM; Fan ST; Liu CL; Chan SC; Ng IO; Wong J
Br J Surg; 2007 Jan; 94(1):78-86. PubMed ID: 17016793
[TBL] [Abstract][Full Text] [Related]
22. Investigation of histological vascular invasion from preoperative evaluation in patients with hepatocellular carcinoma who underwent living donor liver transplantation.
Sakai K; Okajima H; Koshino K; Suzuki T; Nobori S; Matsuyama M; Ushigome H; Ochiai T; Yoshimura N
Transplant Proc; 2012 Mar; 44(2):409-11. PubMed ID: 22410029
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
[TBL] [Abstract][Full Text] [Related]
24. Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center.
Jonas S; Mittler J; Pascher A; Schumacher G; Theruvath T; Benckert C; Rudolph B; Neuhaus P
Liver Transpl; 2007 Jun; 13(6):896-903. PubMed ID: 17538994
[TBL] [Abstract][Full Text] [Related]
25. Prospective study on the outcome of patients with hepatocellular carcinoma registered for living donor liver transplantation: how long can they wait?
Mizuno S; Yokoi H; Shiraki K; Usui M; Sakurai H; Tabata M; Sugimoto K; Takei Y; Yamakado K; Takeda K; Uemoto S; Isaji S
Transplantation; 2010 Mar; 89(6):650-4. PubMed ID: 20048691
[TBL] [Abstract][Full Text] [Related]
26. Living donor liver transplantation for hepatocellular carcinoma in patients exceeding the UCSF criteria.
Fouzas I; Sotiropoulos GC; Lang H; Nadalin S; Beckebaum S; Sgourakis G; Saner FH; Radtke A; Papanikolaou V; Baba HA; Paul A; Broelsch CE; Malagó M
Transplant Proc; 2008 Nov; 40(9):3185-8. PubMed ID: 19010228
[TBL] [Abstract][Full Text] [Related]
27. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S
Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
[TBL] [Abstract][Full Text] [Related]
28. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
[TBL] [Abstract][Full Text] [Related]
29. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence.
Parfitt JR; Marotta P; Alghamdi M; Wall W; Khakhar A; Suskin NG; Quan D; McAllister V; Ghent C; Levstik M; McLean C; Chakrabarti S; Garcia B; Driman DK
Liver Transpl; 2007 Apr; 13(4):543-51. PubMed ID: 17394152
[TBL] [Abstract][Full Text] [Related]
30. Living donor liver transplantation for hepatocellular carcinoma.
Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
[TBL] [Abstract][Full Text] [Related]
31. Comparison between human-telomerase reverse transcriptase mRNA and alpha-fetoprotein mRNA as a predictive value for recurrence of hepatocellular carcinoma in living donor liver transplantation.
Oya H; Sato Y; Yamamoto S; Nakatsuka H; Kobayashi T; Hara Y; Waguri N; Suda T; Aoyagi Y; Hatakeyama K
Transplant Proc; 2006 Dec; 38(10):3636-9. PubMed ID: 17175353
[TBL] [Abstract][Full Text] [Related]
32. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival.
Vakili K; Pomposelli JJ; Cheah YL; Akoad M; Lewis WD; Khettry U; Gordon F; Khwaja K; Jenkins R; Pomfret EA
Liver Transpl; 2009 Dec; 15(12):1861-6. PubMed ID: 19938113
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
[TBL] [Abstract][Full Text] [Related]
34. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
Lee KW; Yi NJ; Suh KS
Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
36. University of California at San Francisco criteria can be applied to living donor liver transplantation for hepatocellular carcinoma: single-center preliminary results in 27 patients.
Jiang XZ; Yan LN; Wen TF; Li B; Zeng Y; Zhao JC; Wang WT; Yang JY; Xu MQ; Chen ZY; Ma YK; Li FG; Gong G
Transplant Proc; 2008 Jun; 40(5):1476-80. PubMed ID: 18589132
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
[TBL] [Abstract][Full Text] [Related]
38. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
39. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin.
Shirabe K; Itoh S; Yoshizumi T; Soejima Y; Taketomi A; Aishima S; Maehara Y
J Surg Oncol; 2007 Mar; 95(3):235-40. PubMed ID: 17323337
[TBL] [Abstract][Full Text] [Related]
40. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.
Facciuto ME; Koneru B; Rocca JP; Wolf DC; Kim-Schluger L; Visintainer P; Klein KM; Chun H; Marvin M; Rozenblit G; Rodriguez-Davalos M; Sheiner PA
Ann Surg Oncol; 2008 May; 15(5):1383-91. PubMed ID: 18320284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
